Research programme: oral protein therapeutics - Allena Pharmaceuticals

Drug Profile

Research programme: oral protein therapeutics - Allena Pharmaceuticals

Alternative Names: ALLN-346; Enzyme therapeutic candidates - Allena Pharmaceuticals; Enzyme therapeutics - Allena Pharmaceuticals

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allena Pharmaceuticals
  • Class Enzymes; Oxidoreductases; Recombinant proteins; Urologics
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hyperuricaemia; Kidney disorders
  • No development reported Urination disorders

Most Recent Events

  • 14 Dec 2017 Allena Pharmaceuticals announces intention to submit IND to US FDA for Hyperuricaemia and chronic Kidney disorders in 1H 2019
  • 01 Dec 2017 Preclinical trials in Hyperuricaemia in USA (PO)
  • 01 Dec 2017 Preclinical trials in Kidney disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top